Current diagnostic methods have limitations in early prediction of dementia.
Objective
Develop an early screening tool to identify persons at high risk of dementia for early intervention.
Methods
We examined amyloid-β protein precursor (AβPP) and its fragments in urine from cognitively normal controls (CNs) and patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD)-dementia using western blotting with different antibodies and developed a colloidal gold lateral flow-based qualitative strip.
Results
Compared with CNs, the amounts of various AβPP fragments with molecular weights of approximately 14, 28, 56, and 68 kDa in patients were greater. We therefore used the strip to detect urine Aβ-containing AβPP fragments and evaluated its potential in multiple aged cohorts from 11 cities in Jiangsu Province, China (n = 4418); Sichuan Provincial People's Hospital (Chengdu, China; n = 408); and the Australian Imaging, Biomarker and Lifestyle Study (AIBL; n = 367). Unitizing Aβ-binding phagocytosis-promoting peptides, the strips showed increasing positivity (9.5–16.9%) with ageing in the Jiangsu cohort and good clinical performance in the Chengdu cohort (κ = 0.704). Significant differences between CNs and patients were found in the AIBL cohort with negative Aβ-PET, those with the slope of Aβ-PET change <1 centiloid per year, those under 75 years of age, or those with a body mass index of 25–30.
Conclusions
Our data indicate the high potential of urine AβPP fragments as biomarkers for MCI and dementia at an early stage and warrant further longitudinal studies.
VillemagneVLBurnhamSBourgeatP, et al.Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol2013; 12: 357–367.
2.
JackCRJrKnopmanDSJagustWJ, et al.Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol2010; 9: 119–128.
3.
JiaJNingYChenM, et al.Biomarker changes during 20 years preceding Alzheimer's disease. N Engl J Med2024; 390: 712–722.
4.
WangJGuBJMastersCL, et al.A systemic view of Alzheimer disease - insights from amyloid-beta metabolism beyond the brain. Nat Rev Neurol2017; 13: 612–623.
5.
HuangXFowlerCLiY, et al.Clearance and transport of amyloid beta by peripheral monocytes correlate with Alzheimer's disease progression. Nat Commun2024; 15: 7998.
6.
HuangXLiYFowlerC, et al.Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. Alzheimers Dement2022; 19: 2084–2094.
7.
GhisoJCaleroMMatsubaraE, et al.Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett1997; 408: 105–108.
8.
TakataMNakashimaMTakeharaT, et al.Detection of amyloid beta protein in the urine of Alzheimer's disease patients and healthy individuals. Neurosci Lett2008; 435: 126–130.
9.
O'BrienRJWongPC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci2011; 34: 185–204.
10.
WillemMTahirovicSBuscheMA, et al.eta-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature2015; 526: 443–447.
11.
ZhangZSongMLiuX, et al.Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease. Nat Commun2015; 6: 8762.
12.
RiceHCde MalmazetDSchreursA, et al.Secreted amyloid-beta precursor protein functions as a GABA(B)R1a ligand to modulate synaptic transmission. Science2019; 363: eaao4827.
13.
TampelliniD. Synaptic activity and Alzheimer's disease: a critical update. Front Neurosci2015; 9: 423.
14.
TurnerPRO'ConnorKTateWP, et al.Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol2003; 70: 1–32.
15.
MattssonNInselPSPalmqvistS, et al.Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis. Nat Commun2016; 7: 10918.
16.
YunSMChoSJJoC, et al.Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease. Arch Gerontol Geriat2020; 87: 103995.
17.
Gomez-PinedoUVillar-QuilesRNGalanL, et al.Immununochemical markers of the amyloid cascade in the hippocampus in motor neuron diseases. Front Neurol2016; 7: 195.
18.
SteinackerPHendrichCSperfeldAD, et al.Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. J Neural Transm (Vienna)2009; 116: 1169–1178.
19.
BiblMMollenhauerBLewczukP, et al.Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord2011; 31: 37–44.
20.
IgnacioIGJordiPVictorM, et al.APP-Derived peptides reflect neurodegeneration in frontotemporal dementia. Ann Clin Transl Neurol2019; 6: 2518–2530.
21.
AlcoleaDVilaplanaESuárez-CalvetM, et al.CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology2017; 89: 178–188.
22.
BargerSWHarmonAD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature1997; 388: 878–881.
23.
MiloschNTanriöverGKunduA, et al.Holo-APP and G-protein-mediated signaling are required for sAPPα-induced activation of the Akt survival pathway. Cell Death Dis2014; 5: e1391.
24.
KosonenRChangJYLeeS, et al.APP96-110 Elicits neuroprotective effects following ischemic insult in animal models. Neurochem Res2023; 48: 2568–2579.
25.
StineWBJungbauerLYuC, et al.Preparing synthetic Abeta in different aggregation states. Methods Mol Biol2011; 670: 13–32.
26.
IdaNHartmannTPantelJ, et al.Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive western blot assay. J Biol Chem1996; 271: 22908–22914.
27.
FowlerCRainey-SmithSRBirdS, et al.Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer's disease. J Alzheimers Dis Rep2021; 5: 443–468.
28.
RoweCCEllisKARimajovaM, et al.Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging2010; 31: 1275–1283.
29.
BourgeatPVillemagneVLDoreV, et al.Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging2015; 36: S159–S166.
30.
KlunkWEKoeppeRAPriceJC, et al.The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement2015; 11: 1–15 e11-14.
31.
BourgeatPDoreVFrippJ, et al.Implementing the centiloid transformation for (11)C-PiB and beta-amyloid (18)F-PET tracers using CapAIBL. Neuroimage2018; 183: 387–393.
LandisJRKochGG. The measurement of observer agreement for categorical data. Biometrics1977; 33: 159–174.
34.
UhlmannRERotherCRasmussenJ, et al.Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nat Neurosci2020; 23: 1580–1588.
35.
SastreMCaleroMPawlikM, et al.Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging2004; 25: 1033–1043.
36.
MullerUCZhengH. Physiological functions of APP family proteins. Cold Spring Harb Perspect Med2012; 2: a006288.
37.
BallardCMobleyWHardyJ, et al.Dementia in Down's syndrome. Lancet Neurol2016; 15: 622–636.
38.
PlummerSVan den HeuvelCThorntonE, et al.The neuroprotective properties of the amyloid precursor protein following traumatic brain injury. Aging Dis2016; 7: 163–179.
39.
da RochaJFda Cruz e SilvaOAVieiraSI. Analysis of the amyloid precursor protein role in neuritogenesis reveals a biphasic SH-SY5Y neuronal cell differentiation model. J Neurochem2015; 134: 288–301.
40.
MattsonMPChengBCulwellAR, et al.Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron1993; 10: 243–254.
41.
Smith-SwintoskyVLPettigrewLCCraddockSD, et al.Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J Neurochem1994; 63: 781–784.
42.
GralleMBotelhoMGWoutersFS. Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J Biol Chem2009; 284: 15016–15025.
43.
GuBJHuangXOuA, et al.Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer's disease. Acta Neuropathol2016; 132: 377–389.
44.
HandokoMGrantMKuskowskiM, et al.Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol2013; 70: 594–599.
45.
GrantMKOHandokoMRozgaM, et al.Human cerebrospinal fluid 6E10-immunoreactive protein species contain amyloid precursor protein fragments. PLoS One2019; 14: e0212815.
46.
BiblMLewczukPEsselmannH, et al.CSF amyloid-beta 1-38 and 1-42 in FTD and AD: biomarker performance critically depends on the detergent accessible fraction. Proteomics Clin Appl2008; 2: 1548–1556.
47.
StruyfsHVan BroeckBTimmersM, et al.Diagnostic accuracy of cerebrospinal fluid amyloid-beta isoforms for early and differential dementia diagnosis. J Alzheimers Dis2015; 45: 813–822.
48.
XuYWangJWangH, et al.2023 Data and strategies of prevention and control for Alzheimer’s disease in China (Chinese). Chinese J Alzheimers Dis Relat Disord2023; 6: 175–192.
49.
GaraiKVerghesePBBabanB, et al.The binding of apolipoprotein E to oligomers and fibrils of amyloid-beta alters the kinetics of amyloid aggregation. Biochemistry2014; 53: 6323–6331.
50.
LiuSParkSAllingtonG, et al.Targeting apolipoprotein E/amyloid beta binding by peptoid CPO_Abeta17-21 P ameliorates Alzheimer's disease related pathology and cognitive decline. Sci Rep2017; 7: 8009.
51.
ZhangFWeiJLiX, et al.Early candidate urine biomarkers for detecting Alzheimer's disease before amyloid-beta plaque deposition in an APP (swe)/PSEN1dE9 transgenic mouse model. J Alzheimers Dis2018; 66: 613–637.
52.
SongZXuYZhangL, et al.Comprehensive proteomic profiling of urinary exosomes and identification of potential non-invasive early biomarkers of Alzheimer's disease in 5XFAD mouse model. Front Genet2020; 11: 565479.
53.
SongZQuYXuY, et al.Microarray microRNA profiling of urinary exosomes in a 5XFAD mouse model of Alzheimer’s disease. Animal Model Exp Med2021; 4: 233–242.
54.
WangYSunYWangY, et al.Urine metabolomics phenotyping and urinary biomarker exploratory in mild cognitive impairment and Alzheimer's disease. Front Aging Neurosci2023; 15: 1273807.
55.
WangYSunYWangY, et al.Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning. Alzheimers Res Ther2023; 15: 191.
56.
WeiYGuBJ. Application and progress of urine detection in early detection of Alzheimer's Disease (Chinese). Chinese J Alzheimers Dis Relat Disord2025; 8: 47–53.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
